Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Privia Health Group, Inc. Market Cap
From what 0 stock analysts predict, the share price for Privia Health Group, Inc. (PRVA) might increase by 34.29% in the next year. This is based on a 12-month average estimation for PRVA. Price targets go from $19 to $37. The majority of stock analysts believe PRVA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
PRVA is a stock in Technology which has been forecasted to be worth $25.61 as an average. On the higher end, the forecast price is $37 USD by Richard Close from Canaccord Genuity and on the lower end PRVA is forecasted to be $19 by Andrew Mok from Barclays.
These are the latest 20 analyst ratings of PRVA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Ha Baird | Outperform | $24 | Maintains | Aug 26, 2024 |
| Sean Dodge RBC Capital | Outperform | $28 | Reiterates | Aug 14, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $20 | Maintains | Jul 9, 2024 |
| Michael Ha Baird | Outperform | $23 | Initiates | May 30, 2024 |
| Andrew Mok Barclays | Equal-Weight | $19 | Maintains | May 20, 2024 |
| Jailendra Singh Truist Securities | Buy | $24 | Maintains | May 15, 2024 |
| Richard Close Canaccord Genuity | Buy | $26 | Maintains | May 10, 2024 |
| Craig Jones Stifel | Buy | $24 | Maintains | May 1, 2024 |
| Daniel Grosslight Citigroup | Buy | $25 | Initiates | Apr 22, 2024 |
| Richard Close Canaccord Genuity | Buy | $37 | Maintains | Mar 19, 2024 |
| Lisa Gill JP Morgan | Overweight | $30 | Maintains | Mar 6, 2024 |
| Andrew Mok Barclays | Equal-Weight | $22 | Initiates | Mar 6, 2024 |
| Gary Taylor TD Cowen | Outperform | $26 | Maintains | Mar 1, 2024 |
| Andrew Mok UBS | Buy | $29 | Maintains | Mar 1, 2024 |
| Jailendra Singh Truist Securities | Buy | $28 | Maintains | Feb 29, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $25 | Maintains | Feb 28, 2024 |
| Adam Ron B of A Securities | Neutral | $21 | Downgrade | Feb 22, 2024 |
| Constantine Davides JMP Securities | Market Outperform | $27 | Initiates | Dec 6, 2023 |
| Lisa Gill JP Morgan | Overweight | $38 | Maintains | Nov 17, 2023 |
| Andrew Mok UBS | Buy | $32 | Maintains | Aug 18, 2023 |
When did it IPO
2021
Staff Count
1,102
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Parth Mehrotra
Market Cap
$2.25B
In 2023, PRVA generated $1.66B in revenue, which was a increase of 22.19% from the previous year. This can be seen as a signal that PRVA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Privia Health Group, Inc. (NASDAQ:PRVA) held its Q2 2024 Earnings Conference Call on August 8, 2024, featuring key executives and analysts from various financial institutions.
Why It Matters - The earnings conference call provides insights into Privia Health's financial performance and strategic direction, which can influence stock valuation and investor sentiment.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Privia Health Group, Inc. (Nasdaq: PRVA) reported its financial results for Q2 and the first half of 2024, ending June 30. Further details on performance were not included.
Why It Matters - Financial results indicate company performance, impacting stock valuation and investment decisions. Positive results may boost investor confidence, while negative outcomes could lead to sell-offs.
Thu, 08 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Privia Health (PRVA) reported its revenue and EPS for Q2 2024, prompting comparisons with Wall Street estimates and year-ago figures for performance evaluation.
Why It Matters - Key metrics compared to Wall Street estimates and year-ago numbers indicate Privia Health's financial health, impacting stock performance and investor sentiment.
Thu, 08 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Privia Health (PRVA) reported Q3 earnings of $0.03 per share, missing the Zacks estimate of $0.05. This is a decline from $0.06 per share in the same quarter last year.
Why It Matters - Privia Health's earnings miss signals potential operational challenges, which could impact future profitability and investor confidence, possibly affecting the stock's performance.
Thu, 01 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Privia Health (PRVA) may not meet earnings expectations in its upcoming report due to a lack of key factors typically needed for a positive outcome.
Why It Matters - Privia Health's lack of key ingredients for an earnings beat suggests potential underperformance, which may negatively impact stock prices and investor sentiment.
Thu, 30 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Privia Health Group, Inc. (Nasdaq: PRVA) will present at the 44th Annual William Blair Growth Stock Conference on June 5, 2024, at 11:00 am ET.
Why It Matters - Privia Health's presentation at a prominent conference could signal growth potential and attract investor interest, impacting stock performance and market perception.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
